✦ LIBER ✦

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

✍ Scribed by Neha Bhagwat, Ross L. Levine, Priya Koppikar

Book ID: 120955305
Publisher: Carden Jennings Publishing
Year: 2013
Tongue: English
Weight: 309 KB
Volume: 97
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-013-1353-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Kinase domain mutations confer resistanc

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

✍ Deshpande, A; Reddy, M M; Schade, G O M; Ray, A; Chowdary, T K; Griffin, J D; Sa 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 544 KB

Myeloproliferative neoplasms 5 years aft

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

✍ Tibes, Raoul; Mesa, Ruben A. 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 209 KB

Uses and Abuses of JAK2 and MPL Mutation

Uses and Abuses of JAK2 and MPL Mutation Tests in Myeloproliferative Neoplasms

✍ Tefferi, Ayalew; Noel, Pierre; Hanson, Curtis A. 📂 Article 📅 2011 🏛 American Society for Investigative Pathology 🌐 English ⚖ 448 KB

The JAK2 46/1 haplotype predisposes to M

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

✍ Jones, A. V.; Campbell, P. J.; Beer, P. A.; Schnittger, S.; Vannucchi, A. M.; Zo 📂 Article 📅 2010 🏛 American Society of Hematology 🌐 English ⚖ 421 KB

JAK2 gene mutation: impact on pathogenes

JAK2 gene mutation: impact on pathogenesis, classification, and management of myeloproliferative neoplasms

✍ Naeem Latif; Troy Guthrie; Fauzia Rana 📂 Article 📅 2010 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 261 KB

Molecular Pathways: Molecular Basis for

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors

✍ Meyer, S. C.; Levine, R. L. 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 512 KB